Objectives: Salivary gland adenoid cystic carcinoma (ACC) is rare, aggressive, and challenging to treat. Many ACCs have a t(6;9) chromosomal translocation resulting in a MYB-NFIB fusion gene, but the clinical significance is unclear. The purposes of this study were to describe the clinicopathologic factors impacting survival and to determine the prevalence and clinical significance of MYB-NFIB fusion.
INTRODUCTION
Adenoid cystic carcinoma (ACC) of the salivary glands is a rare malignancy comprising 10% of salivary gland neoplasms. 1 ACC is slow-growing but aggressive, with high rates of late recurrence and distant metastasis. [2] [3] [4] Treatment for ACC is extremely challenging, with current therapy limited to surgery and/or radiation, and no reliable chemotherapeutic options available for longterm disease control. 1, 4 Previously identified determinants of outcomes for ACC include stage, cervical lymph node metastases, margin status, perineural invasion, minor salivary gland site of origin, and histological pattern. 3, [5] [6] [7] [8] [9] MYB is a transcription factor with important roles in the regulation of cell proliferation, survival, and differentiation. 10 Overactivation of the MYB oncogene has recently been described as a hallmark of ACC, noted in over 80% of ACCs but not in other salivary gland neoplasms. [11] [12] [13] MYB overactivation is often, but not always, the result of a chromosomal translocation, t(6;9)(q22-23;p23-24), resulting in fusion of the MYB oncogene with the transcription factor gene NFIB. This translocation is found in 29% to 86% of ACCs. 11, [13] [14] [15] [16] [17] The MYB-NFIB fusion protein may represent an important new therapeutic target for ACC; however, the clinical and prognostic significance of the MYB-NFIB fusion gene is unclear.
The purposes of this study were to describe our institution's experience with ACC and determine the clinicopathologic factors that impact survival, as well as to assess the prevalence and clinical significance of MYB-NFIB fusion in ACCs treated at our institution.
MATERIALS AND METHODS
This study was approved by the Johns Hopkins School of Medicine Institutional Review Board. Patients treated for ACC of the head and neck at Johns Hopkins medical institutions from 1974 to 2011 were included. The medical records for these patients were retrospectively reviewed, and demographic and disease-related data were recorded.
Fluorescence In Situ Hybridization
Fluorescence in situ hybridization (FISH) was performed on formalin-fixed paraffin-embedded sections in a tissue microarray (TMA) using a commercially available MYB dual-color break-apart probe (ZTV-Z-2143-200, ZytoVision, Germany). The probe is designed to detect translocations involving the chromosomal region 6q23.3 harboring the MYB gene and has two components: a probe labeled with a green fluorochrome that hybridizes proximal to and covers the 5 0 end of the MYB gene, and a probe labeled with an orange fluorochrome that hybridizes 180kb distal to the 3 0 end of the MYB gene. Prior to hybridization, the slide was deparaffinized using a VP 2000 processor (Abbott Molecular, Des Plains, IL). The slides and the MYB probe were codenatured at 808C for 7 minutes and allowed to anneal over night at 378C in a humidified atmosphere. At the end of the incubation, the slides were washed in 23 saline-sodium citrate (SSC)/0.3% Nonidet P-40 for 2 minutes at 728C and for 2 minutes at room temperature in 23 SSC. The slides were counterstained with 4',6-diamidino-2-phenylindole, and a cover slip was applied using Vectashield Mounting Medium (H-1000, Vector Laboratories, Inc., Burlingame, CA). A fluorescence microscope was used to evaluate the probe pattern. Interphase nuclei with two fusion signals of one orange and one green fluorochrome lack rearrangement at band 6q23.3 and are scored as normal (MYB-NFIB negative). A signal pattern consisting of one orange and green fusion signal and one orange and one green signal at distance from each other indicates one normal 6q23.3 locus and one locus affected by a translocation. This pattern was considered a marker of MYB-NFIB translocation (MYB-NFIB positive). In several cases, signal patterns different from the normal (two fusion signals), and the typical rearranged (one fusion, one green, one orange signal) patterns were observed (e.g., one fusion and one green signal, one fusion and one red signal, or amplification of the green signal). These cases were reevaluated using an in-house designed MYB-NFIB fusion probe. The probe identifies the fusion gene on the derivative chromosome 6 that results from a translocation t(6;9)(q22-23;p23-24). The probe covering the MYB gene consists of two BAC clones: RP11-104D9 and RP11-614H6. The BAC DNA is labeled by nick translation with Green-dUTP (Abbott Molecular, Abbott Park, IL). The probe is approximately 360-kb long, covers the MYB gene, and extends beyond the 5 0 end of the gene. The NFIB probe consists also of two BAC clones: RP11-589C16 and RP11-413D24. The BAC DNA is labeled by nick translation with Orange-dUTP (Abbott Molecular). The probe is approximately 370-kb long and covers the 3 0 end of the NFIB gene. The signal pattern in a normal cell consists of two green signals (chromosomes 6) and two orange signals (chromosomes 9). In the case of a rearrangement leading to a MYB-NFIB fusion, the predicted signal pattern is one green signal (chromosome 6), one orange signal (chromosome 9), and one green/orange fusion signal (derivative chromosome 6) (MYB-NFIB positive). Of the 17 cases that could not conclusively be interpreted with the MYB break-apart probe and were reevaluated with the MYB-NFIB fusion probe, only two did not show the gene fusion. These two cases were considered indeterminate.
Statistical Analysis
Descriptive variables were summarized with frequencies and proportions for categorical variables, and medians with 95% confidence intervals (CI) or ranges for continuous variables. The association between clinical variables of interest and MYB-NFIB status was evaluated using a generalized linear model with extension to the binomial family 18, 19 in both univariate and bivariate models, and reported as unadjusted and adjusted prevalence ratios (PR and aPR). Survival rates were estimated using the Kaplan-Meier method. 20 Overall survival (OS) was defined as time from diagnosis to time of death from any cause. Disease-free survival (DFS) was defined as time from diagnosis to time of local, regional, or distant recurrence. Patients with distant metastases at the time of diagnosis, or who died of primary disease without recurrence, were considered to not have received definitive treatment and were excluded from the DFS analysis. Follow-up time was calculated from diagnosis to event of interest or the last known follow-up. Survival curves were compared using the log-rank test for equality of survival functions. Unadjusted and adjusted hazard ratios (HR and aHR) were estimated using the Cox regression model. This retrospective study had 80% power to detect a 2.9-fold or greater difference in survival by MYB-NFIB tumor status. Data analysis was performed using STATA 11.2 (College Station, TX). A P value 0.05 was considered statistically significant.
RESULTS

Clinical and Pathologic Features
The study population was comprised of 158 patients with ACC. Median age at the time of diagnosis was 51.5 years (range, 17-94 years). Clinical and pathologic characteristics are displayed in Table I . The most common tumor site was the parotid gland (N 5 38, 25%). A greater proportion of tumors arose from minor (N 5 85, 57%) than major salivary glands (N 5 65, 43%). Histologically, most tumors were observed to have a cribriform pattern (N 5 78, 70%) and perineural invasion (N 5 68, 83%). Tumors with positive margins (N 5 73, 66%) were significantly more likely to have perineural invasion than those with negative or close margins (78% compared with 22%, P 5 0.026), and were also more likely to have local recurrence (29% compared with 8%, P 5 0.017).
Survival
Median follow-up time was 75.1 months (range, 0.5-360.0 months). Five-year OS was 80% (95% CI 5 71-86%), and median OS was 171.5 months (95% CI 5 131. 9-190.6) . At the time of last follow-up, 78 (53%) of the patients were alive. In univariate analysis, factors associated with decreased OS included older age (HR 5 1.04, 95% CI 5 1.02-1.06, P < 0.001 for each year of age), nodal metastases at the time of neck dissection (HR 5 3.09, 95% CI 5 1.20-7.98, P 5 0.020), and more advanced overall stage (p trend < 0.001) (Table II) . OS was also significantly decreased among patients treated with single modality therapy (surgery or radiation) compared to those treated with surgery and adjuvant radiation (HR 5 3.01, 95% CI 5 1.35-6.72, P 5 0.007). In multivariate analysis, more advanced overall stage (adjusted p trend < 0.001) and older age at diagnosis (aHR 5 1.03, 95% CI 5 1.01-1.05, P 5 0.001) were independently associated with OS (Table II) .
Five-year DFS was 65% (95% CI 5 55-73%) and median DFS was 112.0 months (95% CI 5 88.7-180.4).
More advanced overall stage was associated with decreased DFS (p trend 5 0.014), as were receipt of single modality therapy compared with surgery and adjuvant radiation (HR 5 3.31, 95% CI 5 1.47-6.63, P 5 0.003) and close or positive surgical margins (HR 5 5.98, 95% CI 5 1.30-29.86, P 5 0.029 for close and HR 5 6.93, 95% CI 5 1.64-29.24, P 5 0.008 for positive compared with negative margins). In multivariate analysis, margin status was the only independent predictor of DFS; positive margins were independently associated with an eightfold decrease in DFS (aHR 5 8.80, 95% CI 5 1.25-62.12, P 5 0.029) (Table II) . 
MYB-NFIB Rearrangement
FISH was used to determine MYB rearrangement as a marker of MYB-NFIB fusion tumor status for 93 ACC specimens, of which 91 tumors were considered evaluable for analysis. Of these, 59 (65%) tumors were MYB-NFIB positive and 32 (35%) were MYB-NFIB negative (Fig. 1 ).
There were no significant differences in the clinical and pathologic characteristics of patients with MYB-NFIB tumor status available compared with patients that did not have MYB-NFIB tumor status available (Supp . Table SI) .
Clinicopathologic factors associated with MYB-NFIB positive tumor status were considered (Table III) . Tumors arising from minor salivary glands were more likely to be MYB-NFIB positive (PR 5 1.52, 95% CI 5 1.06-2.18, P 5 0.023), and female gender was significantly associated with MYB-NFIB positive tumor status (PR 5 1.44, 95% CI 5 1.01-2.05, P 5 0.041). Tumors that recurred or had nodal metastases at the time of neck dissection were more likely to be MYB-NFIB positive, although these differences were not statistically significant (P 5 0.15 and P 5 0.14). Age, gender, smoking history, stage, and perineural invasion were not associated with MYB-NFIB status (Table III) . In bivariate analysis, both minor salivary gland origin (aPR 5 1.51, 95% CI 5 1.07-2.12, P 5 0.019) and female gender (aPR 5 1.49, 95% CI 5 1.05-2.11, P 5 0.026) remained significantly associated with MYB-NFIB positive tumor status. In contrast, MYB-NFIB positive tumors exhibited a trend toward decreased DFS. Five-year DFS was 54% (95% CI 5 37%-68%) for MYB-NFIB positive compared with 70% (95% CI 5 44%-85%) for MYB-NFIB negative tumors, and median DFS was 88.7 months (95% CI 5 42.0-127.8) for MYB-NFIB positive compared with 187.2 months (95% CI 5 55.4-318.9) for MYB-NFIB negative tumors (Fig. 2) . However, the association of MYB-NFIB tumor status with decreased DFS was not statistically significant (HR 5 1.53, 95% CI 0.77-3.02, P 5 0.22), and was further attenuated after adjustment for minor versus major salivary gland site of origin (adjusted HR 5 1.18, 95% CI 0.51-2.71, P 5 0.70).
MYB-NFIB and Survival
DISCUSSION
ACC of the head and neck is uncommon and difficult to treat due to its high propensity for late recurrence and distant metastasis, sometimes many years after initial diagnosis and treatment. 1, 3, 4 In this study, we have elucidated important prognostic factors and explored clinicopathologic correlates of the MYB-NFIB fusion gene.
Clinical Outcomes
Similar to previous studies, 3, 5 we found that ACCs were frequently of minor salivary gland origin (57%) and had a high rate of perineural invasion (83%). Recurrences were largely local (31%) or distant (29%), with regional recurrence in only 5% of cases, consistent with the known patterns of ACC recurrence. 3 Our 5-year rates of OS (80%) and DFS (65%) are also consistent with previous reports. 3, 5, 21 Advanced overall stage was the strongest independent predictor of poor OS in our study and was also significantly associated with decreased DFS. Stage was therefore a more important prognostic factor than histologic pattern, perineural invasion, or site of origin. Indeed, overall stage is known to correlate with outcomes for ACC. 3, [6] [7] [8] 21 Margin status was the only factor independently associated with DFS, with a significant trend toward decreasing DFS with closer proximity of disease to the surgical margin. Positive margins were also associated with greater risk of local failure, consistent with previous reports. 22, 23 These associations are not surprising, especially given that in this and other studies, 3 tumors with positive margins were also significantly more likely to demonstrate perineural invasion. Tumors that are challenging to surgically extirpate appear to have a more aggressive biological phenotype and higher likelihood of recurrence. The current treatment paradigm for ACC with positive margins is surgical resection followed by adjuvant radiation therapy, 4, 24, 25 and our results support the indication for adjuvant therapy in these cases.
MYB-NFIB Tumor Status
The MYB oncogene is overexpressed in 89% to 97% ACCs of the head and neck. 11, 13 A subset of these (29%-86%) are characterized by an activating MYB-NFIB fusion resulting from a variable balanced t(6;9)(q22-23;p23-24) translocation event that is not found in other salivary gland cancers. 11, 13, [15] [16] [17] Overexpression of MYB mRNA and the Myb transcription factor protein are associated with the MYB-NFIB fusion, but also occur independent of the translocation, suggesting additional mechanisms of MYB dysregulation. 11, 13, 15, 16 The combination of an initial MYB break-apart probe with a confirmatory MYB-NFIB fusion probe that was used for the FISH assay in this study has not previously been used in ACC of the head and neck. The MYB break-apart probe alone detects a break in the 6q23.2-q23.3 locus containing the MYB gene that most likely results in a MYB-NFIB fusion gene, as has been well described, 13, 14, 17 and our use of a confirmatory MYB-NFIB fusion probe ensured that indeterminate cases were properly categorized. The prevalence of MYB-NFIB positive tumors in this study was 65%, which is similar to previous FISH studies in formalin-fixed tissue. 11, 15, 17 The clinical significance, if any, of the MYB-NFIB fusion gene has not been well established. We demonstrated a higher prevalence of the MYB-NFIB fusion in tumors from minor salivary glands and among females, and a trend toward a higher likelihood of recurrence and decreased DFS with MYB-NFIB positive tumor status, although there was no association with OS. The significance of these results is unclear. Importantly, our sample size was underpowered to detect with certainty the observed difference in DFS by MYB-NFIB status (HR 5 1.53, 95% CI 0.77-3.02, P 5 0.22), which was further attenuated after adjusting for the fact that MYB-NFIB positive tumors were predominantly from minor salivary glands. However, several previous studies have also reported borderline associations of the MYB-NFIB fusion in ACC with poor prognostic parameters, including perineural invasion, 15 local recurrence, 15 and decreased overall survival. 16 Taken together with our study, this suggests a possible trend toward more aggressive disease with MYB-NFIB positive tumor status. Larger studies are necessary to determine with certainty whether the MYB-NFIB fusion is of prognostic significance, or is simply a biomarker of ACC carcinogenesis and potential therapeutic target.
It may be the case that MYB overexpression, independent of the mechanism by which it occurs, is a key event in ACC pathogenesis. Indeed, current evidence indicates that MYB is dysregulated by diverse and complex mechanisms in ACC, 13, 17 and overexpression of the MYB transcript 5 0 end was found in one study to be independently associated with decreased OS. 16 In this scenario, the weak associations of MYB-NFIB tumor status with prognosis found in ours and other studies may simply reflect a greater importance of MYB overexpression than the MYB-NFIB fusion per se in influencing outcomes. Sequencing studies have suggested a possible separate role for NFIB as well. 17, 26 Further research is required to describe the role of MYB or NFIB dysregulation individually and in the context of the MYB-NFIB fusion.
Strengths and Limitations
The strengths of this study are the report of clinicopathologic variables that impact outcomes in ACC, contributing to our understanding of prognostic determinants for this rare disease. In addition, the MYB breakapart and MYB-NFIB fusion FISH assay is a new tool that may be used in studying the role of the MYB-NFIB fusion and MYB alterations in ACC. However, this assay is limited in that it is possible that a subset of tumors with a MYB translocation pattern on FISH actually harbored an atypical translocation. In addition, detection of the MYB-NFIB translocation by RT-PCR has been shown to be lower in formalin-fixed compared with frozen tissue (44%-57% compared with 86%); 11, 13, 15, 17 therefore, the use of formalin-fixed tissue in the present study may lower the sensitivity of our assay for MYB-NFIB positive tumor status and limit the interpretation of clinicopathologic correlates. Other limitations of this study include the retrospective nature of the medical chart review and the relatively small sample size with FISH assay results available, resulting in inadequate power to detect significant survival differences by MYB-NFIB tumor status.
CONCLUSION
In summary, stage and margin status are important prognostic indicators for ACC. The MYB-NFIB fusion may be more prevalent in tumors with aggressive features but was not significantly associated with prognosis in our study. Further research is indicated to determine both the clinical and therapeutic significance of the MYB-NFIB fusion gene.
